



## Emerging Applications of "Omics" in Personalized Medicine and Drug Discovery

Guest Editor:

**Dr. Yana Sandler**

Department of Chemistry,  
Cleveland State University,  
Cleveland, OH 44115, USA

Deadline for manuscript  
submissions:

**closed (31 March 2020)**

### Message from the Guest Editor

Various "omics" technologies have substantially contributed to our understanding of complex phenotypes, genotypes, and disease pathophysiologies. In the drug development field, "omics" provide valuable tools in the identification of new therapeutic targets and a new paradigm in safety and efficacy studies. Although many challenges still have to be addressed for the bench to bedside translation, "omics" platforms have the potential to transform medicine from traditional to more personalized approach while advancing prognostic, diagnostic and therapeutic outcomes markers. Consequently, the more personalized approach will lay the foundation to more effective medical interventions for the benefit of patients and healthcare providers.

We are inviting the submission of original and review articles to a Special Issue of the JPM to cover the expanding field of "omics" integration in personalized medicine and drug discovery. The manuscript can cover translational, preclinical and clinical studies or innovative technologies and network analysis developments that challenge and advance the field.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA

2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)